Evidence map›Paper›PMID 41645921›Full record

Observational studyJournal of the European Academy of Dermatology and Venereology : JEADV2026

Multi-omics profiling of chronic immune-mediated skin diseases: SKINERGY protocol and strategic evaluation.

N G Koster, J M P A van den Reek, E M G J de Jong, S van Beugen, A I M van Laarhoven, I Haeck, M de Bruin-Weller, M L Schuttelaar, B Horvath, A Gostyński and 35 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of the European Academy of Dermatology and Venereology : JEADV, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

45 authors.

N G KosterDivision BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.ORCID https://orcid.org/0009-0001-9195-8729
J M P A van den ReekDept. Dermatology, Radboud University Medical Centre, Nijmegen, The Netherlands.ORCID https://orcid.org/0000-0002-3642-2673
E M G J de JongDept. Dermatology, Radboud University Medical Centre, Nijmegen, The Netherlands.
S van BeugenLeiden University, Institute of Psychology, Health, Medical and Neuropsychology Unit, Leiden, The Netherlands.
A I M van LaarhovenLeiden University, Institute of Psychology, Health, Medical and Neuropsychology Unit, Leiden, The Netherlands.
I HaeckDepartment of Dermatology, University Medical Center Utrecht, Utrecht, The Netherlands.
M de Bruin-WellerDepartment of Dermatology, University Medical Center Utrecht, Utrecht, The Netherlands.
M L SchuttelaarDepartment of Dermatology, University Medical Center Groningen, Groningen, the Netherlands.
B HorvathDepartment of Dermatology, University Medical Center Groningen, Groningen, the Netherlands.
A GostyńskiDepartment of Dermatology, University Medical Center Maastricht+, Maastricht, the Netherlands.ORCID https://orcid.org/0000-0002-1091-2914
A KnulstDepartment of Dermatology, University Medical Center Utrecht, Utrecht, The Netherlands.
M H VermeerDepartment of Dermatology, Leiden University Medical Center, Leiden, The Netherlands.ORCID https://orcid.org/0000-0002-5872-4613
L NguyenDepartment of Dermatology, Leiden University Medical Center, Leiden, The Netherlands.
L GerbensDepartment of Dermatology, Amsterdam Institute for Public Health, Immunology and Infectious Diseases, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
P SpulsDepartment of Dermatology, Amsterdam Institute for Public Health, Immunology and Infectious Diseases, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
M A Middelkamp-HupDepartment of Dermatology, Amsterdam Institute for Public Health, Immunology and Infectious Diseases, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
V ExadaktylosCentre for Human Drug Research (CHDR), Leiden, The Netherlands.
T Niemeyer-van der KolkCentre for Human Drug Research (CHDR), Leiden, The Netherlands.ORCID https://orcid.org/0000-0002-3221-1609
A R SchraderDepartment of Pathology, Leiden University Medical Center, Leiden, the Netherlands.
A M SluijmersDutch Association for People with Lupus, APS, Scleroderma and MCTD, Utrecht, the Netherlands.
J VersteegDutch Association for Patients with Hidradenitis, Utrecht, The Netherlands.
B W M ArentsDutch Association for People with Atopic Dermatitis, Nijkerk, the Netherlands.ORCID https://orcid.org/0000-0001-6884-8014
I van EeDutch Association for People with Psoriastic Disease, Nijkerk, the Netherlands.
J L A G van der ZonDutch Association for People with Psoriastic Disease, Nijkerk, the Netherlands.
M de LeeuwDutch Cutaneous Lymphoma Patient Advocacy Group, Utrecht, The Netherlands.
T de LeeuwDutch Cutaneous Lymphoma Patient Advocacy Group, Utrecht, The Netherlands.
P van den BroekDutch Skin Alliance, Utrecht, The Netherlands.
C BerkhofDutch Patient Platform Advocacy Group Urticaria, Utrecht, The Netherlands.
D VellingaAlrijne Hospital Leiderdorp, Leiderdorp, The Netherlands.
S WeidingerUniversity Hospital Kiel Schleswig Holstein, Kiel, Germany.
S DubracMedical University of Innsbruck, Innsbruck, Austria.
Y LiHelmholtz Centre for Infection Research, Hannover Medical School, Hannover, Germany.
M van SteenselNanyang Technological University, Singapore.
M Marchetti-DeschmannTechnical University Wien, Vienna, Austria.
M MaurerCharité University Hospital, Berlin, Germany.ORCID https://orcid.org/0000-0002-4121-481X
H van der ZeeDepartment of Dermatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0002-2874-7726
J DammanDepartment of Dermatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0001-5070-6739
D J HijnenDept. Dermatology, Radboud University Medical Centre, Nijmegen, The Netherlands.
F WijkUniversity Medical Center Utrecht, Center of Translational Immunology, Utrecht, the Netherlands.
M M B SeygerDept. Dermatology, Radboud University Medical Centre, Nijmegen, The Netherlands.ORCID https://orcid.org/0000-0003-0516-8294
H RöckmannDepartment of Dermatology, University Medical Center Utrecht, Utrecht, The Netherlands.
D M W BalakDepartment of Dermatology, Leiden University Medical Center, Leiden, The Netherlands.
M B A van DoornCentre for Human Drug Research (CHDR), Leiden, The Netherlands.
R RissmannDivision BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.
Next Generation ImmunoDermatology (NGID) consortium

Funding

Nederlandse Organisatie voor Wetenschappelijk Onderzoek NWA.1389.20.182
6 · The paper itself

Abstract

backgroundThe Dutch flagship project Next Generation ImmunoDermatology (NGID) aims to profile five chronic immune-mediated inflammatory skin diseases: atopic dermatitis (AD), plaque psoriasis (PSO), hidradenitis suppurativa (HS), chronic spontaneous urticaria (CSU) and cutaneous lupus erythematosus (CLE) in comparison with cutaneous T-cell lymphoma subtype mycosis fungoides (MF) and healthy volunteers. Within NGID, a clinical study entitled: 'SKIN disease profiling by an Exploratory, pRospective, biomarker study in dermatoloGY practice (SKINERGY)' will be conducted as a multicentre, parallel-cohort, open-label, observational, longitudinal basket study.

objectivesObjectives include evaluation of disease-related characteristics in comparison to those of healthy volunteers and evaluation of biomarkers for disease stratification and (targeted) treatment response in patients in a real-world clinical setting. Additionally, differences and similarities in disease characteristics between diseases, changes over time, and profiles of responders versus non-responders will be evaluated.

methodsPatients with AD (N = 120), PSO (N = 160), HS (N = 80), CSU (N = 120) and CLE (N = 120) will be enrolled in groups of N ≤ 40 patients per treatment. Matched healthy volunteers (N = 120) and the MF cohort (N = 120) will serve as control groups. Assessments include blood sampling, skin punch biopsies, tape stripping, skin swabs, (multimodal) imaging, tele-health and patient- and physician-reported outcomes. This manuscript describes the study protocol prior to data collection and its strategic evaluation of multi-omics profiling. Patient advocacy groups co-defined the research agenda and contributed to study design and informed consent document development, ensuring alignment with patients' needs and real-world relevance.

resultsSKINERGY will generate a machine learning-ready dataset with information about changes in various biomarkers over time, including histology, metabolomics, spatial proteomics, transcriptomics, lipidomics, microbiomics, imaging biomarkers, tele-health, patient-reported outcome measures (PROMs) and clinical parameters.

conclusionsIdentified biomarker profiles within SKINERGY may guide targeted treatment selection, enhance targeted therapeutic response in clinical practice and improve understanding of disease pathology in chronic immune-mediated skin diseases.

Indexed as

MultiomicsSkin DiseasesBiomarkersChronic DiseaseChronic UrticariaDermatitis, AtopicHidradenitis SuppurativaHumansLongitudinal StudiesLupus Erythematosus, CutaneousMaleMycosis FungoidesProspective StudiesPsoriasisBiomarkersatopic dermatitischronic spontaneous urticariacutaneous lupus erythematosushidradenitis suppurativainflammatory skin diseasesmulti‐omics deep phenotypingmycosis fungoides‐type cutaneous t‐cell lymphomapersonalized medicinepsoriasis

Identifiers

PMID41645921
PMCPMC13505733

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.